sST2 and Big ET-1 as Alternatives of Multi-Biomarkers Strategies for Prognosis Evaluation in Patients Hospitalized with Heart Failure

References

• GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. doi:10.1016/S0140-6736(18)32279-7
   PubMed Web of Science ®Google Scholar
• Jones NR, Roalfe AK, Adoki I, et al. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. 2019;21(11):1306–1325. doi:10.1002/ejhf.1594
   PubMed Web of Science ®Google Scholar
• Ibrahim NE, Januzzi JL. Established and emerging roles of biomarkers in heart failure. Circ Res. 2018;123(5):614–629. doi:10.1161/CIRCRESAHA.118.312706
   PubMed Web of Science ®Google Scholar
• Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2018. Chin J Heart Fail Cardiomyop. 2018;2(4):196–225. doi:10.3760/cma.j.issn.2096-3076.2018.12.002
   Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a Report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895–e1032. doi:10.1161/CIR.0000000000001063
   PubMed Web of Science ®Google Scholar
• Aimo A, Vergaro G, Ripoli A, et al. Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure. JACC Heart Fail. 2017;5(4):287–296. doi:10.1016/j.jchf.2016.12.016
   PubMed Web of Science ®Google Scholar
• Huang H, Huang B, Li Y, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014;16(1):15–24. doi:10.1093/eurjhf/hft132
   PubMed Web of Science ®Google Scholar
• Ter Maaten JM, Kremer D, Demissei BG, et al. Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. Eur J Heart Fail. 2019;21(6):732–743. doi:10.1002/ejhf.1437
   PubMed Web of Science ®Google Scholar
• Castiglione V, Aimo A, Vergaro G, et al. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev. 2022;27(2):625–643. doi:10.1007/s10741-021-10105-w
   PubMed Web of Science ®Google Scholar
• Demissei BG, Cotter G, Prescott MF, et al. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. Eur J Heart Fail. 2017;19(8):1001–1010. doi:10.1002/ejhf.749
   PubMed Web of Science ®Google Scholar
• De Buyzere ML. Multi-biomarker risk stratification in heart failure: a story of diminished marginal returns after Herculean efforts? Eur J Heart Fail. 2018;20(2):278–280. doi:10.1002/ejhf.1035
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Ordonez-Llanos J. Multiple biomarker strategies for risk stratification in heart failure. Clin Chim Acta. 2015;443:120–125. doi:10.1016/j.cca.2014.10.023
   PubMed Web of Science ®Google Scholar
• Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715–731. doi:10.1002/ejhf.1494
   PubMed Web of Science ®Google Scholar
• Lam CSP, Li YH, Bayes-Genis A, et al. The role of N-terminal pro-B-type natriuretic peptide in prognostic evaluation of heart failure. J Chin Med Assoc. 2019;82(6):447–451. doi:10.1097/JCMA.0000000000000102
   PubMed Web of Science ®Google Scholar
• Miller WL, Hartman KA, Grill DE, et al. Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. Clin Chem. 2009;55(1):78–84. doi:10.1373/clinchem.2008.108928
   PubMed Web of Science ®Google Scholar
• Peacock WFT, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358(20):2117–2126. doi:10.1056/NEJMoa0706824
   PubMed Web of Science ®Google Scholar
• Tentzeris I, Jarai R, Farhan S, et al. Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail. 2011;13(7):726–733. doi:10.1093/eurjhf/hfr049
   PubMed Web of Science ®Google Scholar
• Arcari L, Luciani M, Cacciotti L, et al. Coronavirus disease 2019 in patients with cardiovascular disease: clinical features and implications on cardiac biomarkers assessment. J Cardiovasc Med. 2021;22(11):832–839. doi:10.2459/JCM.0000000000001252
   Google Scholar
• O’Meara E, Prescott MF, Claggett B, et al. Independent prognostic value of serum soluble ST2 measurements in patients with heart failure and a reduced ejection fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018;11(5):e004446. doi:10.1161/CIRCHEARTFAILURE.117.004446
   PubMed Web of Science ®Google Scholar
• Emdin M, Aimo A, Vergaro G, et al. sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T. J Am Coll Cardiol. 2018;72(19):2309–2320. doi:10.1016/j.jacc.2018.08.2165
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Mebazaa A, Di Somma S. ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel. Am J Cardiol. 2015;115(7 Suppl):26b–31b. doi:10.1016/j.amjcard.2015.01.037
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA, Manzano-Fernández S, Boronat M, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail. 2011;13(7):718–725. doi:10.1093/eurjhf/hfr047
   PubMed Web of Science ®Google Scholar
• Wang Z, Pan X, Xu H, et al. Serum soluble ST2 is a valuable prognostic biomarker in patients with acute heart failure. Front Cardiovasc Med. 2022;9:812654. doi:10.3389/fcvm.2022.812654
   PubMed Web of Science ®Google Scholar
• Zhang CL, Xie S, Qiao X, et al. Plasma endothelin-1-related peptides as the prognostic biomarkers for heart failure: a PRISMA-compliant meta-analysis. Medicine. 2017;96(50):e9342. doi:10.1097/MD.0000000000009342
   PubMed Web of Science ®Google Scholar
• Mo R, Yang YM, Yu LT, et al. Elevated plasma big endothelin-1 at admission is associated with poor short-term outcomes in patients with acute decompensated heart failure. Front Cardiovasc Med. 2021;8:629268. doi:10.3389/fcvm.2021.629268
   PubMed Web of Science ®Google Scholar
• Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol. 2013;168(3):2186–2194. doi:10.1016/j.ijcard.2013.01.228
   PubMed Web of Science ®Google Scholar
• Jackson CE, Haig C, Welsh P, et al. The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. Eur J Heart Fail. 2016;18(12):1491–1498. doi:10.1002/ejhf.543
   PubMed Web of Science ®Google Scholar